Clinical trials: Covid19 Vaccine
COVID-19, Pulmonary Tuberculosis
Study on Three Doses of an Inactivated COVID-19 Vaccine in Chinese Pulmonary Tuberculosis Patients
This is a randomized, double-blind, parallel-controlled study, for evaluation of safety and immunogenicity of three doses of an inactivated COVID-19 vaccine (CoronaVac) in pulmonary tuberculosis patients aged 18-75 years.
- Trial name
- NCT05148949
- Testing
- Standard dosage inactivated vaccine, Double dosage inactivated vaccine
- Where
- 6 sites in China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
COVID-19, Vaccine Hesitancy
COVID-19 Disease & Vaccine Survey in Africa
The COVID-19 pandemic is a public health concern; for which the WHO recommends protective measures and vaccination. There is inadequate data on the impact of COVID-19 vaccination and control measures in Africa.
- Trial name
- NCT05950243
- Testing
- Questionnaire
- Where
- Canada
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Salem Anaesthesia Pain Clinic
COVID-19 Lower Respiratory Infection
Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose)
This study will assess the safety and immunogenicity of AG0302-COVID19 in healthy volunteers.
- Trial name
- NCT04993586
- Testing
- AG0302-COVID19 for Intramuscular Injection, AG0302-COVID19 for Intradermal Injection
- Where
- 6 sites in Japan
- Volunteers
- 422 people, healthy volunteers welcome
- Sponsor
- AnGes, Inc.
Rheumatic Diseases
The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)
Based on the experience with influenza, pneumococcal, and shingles vaccinations in rheumatic disease populations, it is clear that some disease modifying anti-rheumatic drugs and the immunomodulatory therapies used to treat…
- Trial name
- NCT05543642
- Testing
- Hepatitis A vaccine, Diphtheria, pertussis, and tetanus booster vaccine
- Where
- 7 sites in United States
- Volunteers
- 129 people
- Sponsor
- Oregon Health and Science University
Vaccine Adverse Reaction, Gender
Anti-COVID-19 Vaccine Side Effects
In 2021 and following the COVID-19 (corona virus disease 2019) pandemic, different vaccines were initially authorized in Italy and Lebanon. Notably, vaccine side effects were poorly recorded.
- Conditions
- Vaccine Adverse Reaction, Gender, COVID-19 Vaccine Adverse Reaction
- Trial name
- VAX-IT-LEB (NCT05735769)
- Where
- Italy
- Volunteers
- 2,797 people, healthy volunteers welcome
- Sponsor
- University of Bari
SARS-CoV-2
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
The purpose of this study is to investigate the immunogenicity and safety of mRNA COVID-19 variant-containing vaccine formulations against the vaccine-matched variants and newly emerged variants of severe acute respiratory…
- Trial name
- NCT06585241
- Testing
- mRNA-1273 Variant-containing Formulation
- Where
- 6 sites in United States
- Volunteers
- 1,144 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Kidney Transplant, Myeloma
Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults
The primary endpoint of this study is to compare the humoral response (titre and neutralizing capacity of induced antibodies) against SARS-CoV-2 following vaccination with BNT162b2 (Pfizer BioNTech) in immunocompromised persons…
- Conditions
- Kidney Transplant, Myeloma, Cancer, Hematologic Malignancy
- Trial name
- EREVA (NCT04952766)
- Testing
- Biological samples
- Where
- France
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Régional d'Orléans
Covid19
Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Ad5-nCoV) in Adults 18 Years of Age and Older, Living With HIV
A randomized, double-blind, placebo -controlled, phase IIb clinical trial to evaluate the efficacy, safety and immunogenicity of one or two doses of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in adults 18…
- Trial name
- COVID-19 (NCT05005156)
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV)
- Where
- 4 sites in Argentina
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Fundación Huésped
Influenza, Human, Pneumonia, Pneumococcal
Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4
Subjects will be recruited and divided into 3 groups: Experimental Group (384 subjects): 1st dose : combined vaccination of COVAX+IIV4, 2nd dose: combined vaccination of COVAX+PPV23; Control Group A (384 subjects): 1st dose…
- Conditions
- Influenza, Human, Pneumonia, Pneumococcal, Covid19
- Trial name
- NCT04790851
- Testing
- COVAX+IIV4; COVAX+PPV23, COVAX only (1st and 2nd dose), IIV4 for the 1st dose and PPV23 for the 2nd dose
- Where
- 3 sites in China
- Volunteers
- 1,133 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Cancer, Immune Checkpoint Inhibitors
COVICI-SURV: COVID-19 Vaccination Around ICI Start and Survival
COVICI-SURV is a nationwide, retrospective observational cohort study using the French national health data system (SNDS) to evaluate whether COVID-19 vaccination, particularly mRNA vaccination, received within 100 days before or…
- Conditions
- Cancer, Immune Checkpoint Inhibitors, COVID-19 Vaccination, Survival
- Trial name
- COVICI-SURV (NCT07729241)
- Where
- France
- Volunteers
- 95,015 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
HIV Infections
Vaccines in a Time of Dual Pandemic: COVID-19 Vaccine in People With HIV
This is a prospective, non-randomized observational study to examine SARS-CoV-2 vaccine immunogenicity, immune activation and HIV reservoirs in people with HIV infection in comparison with HIV-negative individuals, in those aged…
- Trial name
- NCT06731127
- Where
- Canada
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Covid19
Study of a Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Adjuvanted Inactivated Vaccine in Healthy Adults
This phase I study is designed as double-blinded, randomised, placebo controlled, three-armed study composed of two different dose arms of protective adjuvanted inactivated vaccine against SARS-CoV-2 in dose escalations (first…
- Trial name
- COVID-19 (NCT04866069)
- Testing
- SARS-CoV-2 vaccine
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Osman ERGANIS, PhD, Prof
Multiple Sclerosis, Covid19
Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis
This observational study is intended to evaluate the effect of disease modifying therapies on antibody responses to the mRNA-1273 vaccine (Moderna) for COVID-19.
- Trial name
- NCT04834401
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- St. Barnabas Medical Center
COVID-19 Vaccines
Improving COVID-19 Vaccine Uptake in Nursing Homes
SARS-CoV-2 vaccine, now being administered to skilled nursing facility (SNF) residents and staff, has highly variable acceptance between facilities.
- Trial name
- NCT04732819
- Testing
- High touch multi-pronged behavioral intervention
- Where
- 4 sites in United States
- Volunteers
- 23,768 people
- Sponsor
- Brown University
Covid19, Immunosuppression
Humoral and Cellular Immune Response to COVID-19 Vaccines in Immunocompromised and Healthy Individuals
Currently, the efficacy of COVID-19 vaccination in immunodeficient patients is unknown. Here the investigators aim to evaluate the efficacy of COVID-19 vaccines in immunodeficient patients compared to healthy controls.
- Trial name
- CoVVac (NCT04858607)
- Testing
- Blood sample, Saliva sample
- Where
- Austria
- Volunteers
- 373 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
COVID-19 Vaccine
Efficacy and Safety of Covid-19 Vaccine in Cardiac Patients
Efficacy and safety of covid-19 vaccine in Cardiac patients
- Trial name
- NCT05348629
- Where
- 2 sites in Egypt
- Volunteers
- 50 people
- Sponsor
- Mina sobhi said fam
COVID-19
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
This is a multicenter, randomized, double blind, parallel placebo controlled, phase 3 clinical trial to evaluate the protective efficacy, safety and immunogenicity of inactivated SARS-CoV-2 vaccines in healthy population 18 years…
- Trial name
- Covid-Peru (NCT04612972)
- Where
- Peru
- Volunteers
- 12,000 people, healthy volunteers welcome
- Sponsor
- Universidad Peruana Cayetano Heredia
Covid19
Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults
This study is a randomized, double-blinded clinical Trial, to evaluate the non-inferiority of the commercial scale Inactivated SARS-CoV-2 vaccine against that of the pilot scale among adults aged 26-45 years, and the…
- Trial name
- NCT04617483
- Testing
- Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14, Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14, Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly
- Where
- China
- Volunteers
- 1,040 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
COVID-19, SARS-CoV-2
A Randomized Study to Determine the Expression of the Furin Protein in Patients With SARS-CoV-2 and Vaccinated Against Coronavirus
The rapid spread of SARS-CoV-2 (also known as 2019-nCoV and HCoV-19 1), a novel beta coronavirus B lineage (βCoV), has sparked a global coronavirus disease (COVID-19) pandemic.
- Conditions
- COVID-19, SARS-CoV-2, Furin, RGMc Processing
- Trial name
- NCT05104840
- Where
- 9 sites in United States, India and 1 more
- Volunteers
- 2,432 people
- Sponsor
- Center Trials & Treatment
SARS-CoV-2, COVID-19
Informing the Population of Their Level of Protection Against COVID-19 in Monaco: a Prospective Study (MonaVacc)
Vaccines against the coronavirus type 2 causing severe acute respiratory syndrome Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have been created in a short period of time due to the rapid spread of the virus.
- Conditions
- SARS-CoV-2, COVID-19, Vaccines, Antibody
- Trial name
- MonaVacc (NCT05084950)
- Where
- Monaco
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Centre Scientifique de Monaco
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.